Wednesday, July 8, 2026

pharma · Patency of the Ductus Arteriosus · Atopic Dermatitis · CNTB

S.L

S.L is a pharma organization headquartered in SAN DIEGO, CA, EU. It trades on NYSE under ticker CNTB. Primary therapeutic focus areas include Patency of the Ductus Arteriosus, Atopic Dermatitis, Chronic Rhinosinusitis Wi

SAN DIEGO, CA, EU HQ
Public company Type
CNTB · NYSE Ticker
Company details
Status
Public
HQ
SAN DIEGO, CA, EU
Programs
15
Drugs
11
Patents
179
Clinical program

CBP-201

Phase 3 · small molecule · Atopic Dermatitis

CBP-201 for Atopic Dermatitis is a Phase 3 program (small_molecule) at S.L with 2 ClinicalTrials.gov record(s).

← All S.L projects Phase 3 small molecule active

Internal code CBP-201-CN003

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
S.L
Phase
Phase 3
Modality
small_molecule
Indication
Atopic Dermatitis
Status
active
Trials
2

Clinical trials